{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:43:24Z","timestamp":1792035804358,"version":"4.4.0"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>No effective antiviral therapies are currently available to treat disease after infection with yellow fever virus (YFV). A Syrian golden hamster model of yellow fever (YF) was used to characterize the effect of treatment with BCX4430, a novel adenosine nucleoside analog. Significant improvement in survival was observed after treatment with BCX4430 at 4 mg\/kg of body weight per day dosed intraperitoneally (i.p.) twice daily (BID). Treatment with BCX4430 at 12.5 mg\/kg\/day administered i.p. BID for 7 days offered complete protection from mortality and also resulted in significant improvement of other YF disease parameters, including weight loss, serum alanine aminotransferase levels (6 days postinfection [dpi]), and viremia (4 dpi). In uninfected hamsters, BCX4430 at 200 mg\/kg\/day administered i.p. BID for 7 days was well tolerated and did not result in mortality or weight loss, suggesting a potentially wide therapeutic index. Treatment with BCX4430 at 12 mg\/kg\/day i.p. remained effective when administered once daily and for only 4 days. Moreover, BCX4430 dosed at 200 mg\/kg\/day i.p. BID for 7 days effectively treated YF, even when treatment was delayed up to 4 days after virus challenge, corresponding with peak viral titers in the liver and serum. BCX4430 treatment did not preclude a protective antibody response, as higher neutralizing antibody (nAb) concentrations corresponded with increasing delays of treatment initiation, and greater nAb responses resulted in the protection of animals from a secondary challenge with YFV. In summary, BCX4430 is highly active in a hamster model of YF, even when treatment is initiated at the peak of viral replication.<\/jats:p>","DOI":"10.1128\/aac.03368-14","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T06:40:17Z","timestamp":1409035217000},"page":"6607-6614","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":94,"title":["BCX4430, a Novel Nucleoside Analog, Effectively Treats Yellow Fever in a Hamster Model"],"prefix":"10.1128","volume":"58","author":[{"given":"Justin G.","family":"Julander","sequence":"first","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta","family":"Bantia","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Taubenheim","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena M.","family":"Minning","sequence":"additional","affiliation":[{"name":"MedExpert Consulting, Inc., Indialantic, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Kotian","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Morrey","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald F.","family":"Smee","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Sheridan","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarlagadda S.","family":"Babu","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.10.009"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2009.12.011"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ento.52.110405.091454"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.6"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.12.002"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13027"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/320199"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.08.008"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2006.74.1084"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/320200"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01635-10"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01494-06"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.03.004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01074-08"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2004.71.306"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.03.023"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.034"},{"key":"e_1_3_2_19_2","first-page":"493","article-title":"A simple method of estimating fifty percent endpoint","volume":"27","author":"Reed LJ","year":"1938","unstructured":"ReedLJMuenchCH. 1938. A simple method of estimating fifty percent endpoint. Am. J. Hyg. (Lond.) 27:493\u2013497.","journal-title":"Am. J. Hyg. (Lond.)"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-07"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1981.30.431"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03368-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03368-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:45:41Z","timestamp":1645483541000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03368-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1128\/AAC.03368-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03368-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}